MARINUS PHARMACEUTICALS, INC.
DelistedCIK 1267813fmd_13KAKAP692058MNYPJEAYQ22APManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2013 to Sep 30, 2024, 47 periods
Latest annual · FY2023
Millions- Total revenues
- 31
- Gross profit
- 14
- Operating income
- (131)
- Net income
- (141)
Latest quarter · Q3 FY2024
Millions- Total revenues
- 9
- Operating income
- (21)
- Net income
- (24)
- Free cash flow
- (21)
Key stats
Open AnalysisCompound annual growth
- Revenue, 3 yearsFY2020 to FY2023
- +162.3%
- Revenue, 5 yearsFY2018 to FY2023
- n/m
- Net income, 5 yearsFY2018 to FY2023
- n/m
MARINUS PHARMACEUTICALS, INC. financials: quick answers
Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.
| Metric | FY2023 | FY2022 | Change | Source |
|---|---|---|---|---|
| Revenue | $31 million | $25.5 million | +21.6% | 10-K 2024-03-05 · proof |
| Operating income | -$131.5 million | -$112.8 million | 10-K 2024-03-05 · proof | |
| Net income | -$141.4 million | -$19.8 million | 10-K 2024-03-05 · proof | |
| Cash from operating activities | -$118 million | -$112.9 million | 10-K 2024-03-05 · proof | |
| Total assets | $170.9 million | $259.5 million | -34.1% | 10-K 2024-03-05 · proof |
| Total liabilities | $154.1 million | $143.5 million | +7.4% | 10-K 2024-03-05 · proof |
| Cash and cash equivalents | $120.6 million | $240.6 million | -49.9% | 10-K 2024-03-05 · proof |
- What was MARINUS PHARMACEUTICALS, INC.'s revenue in fiscal 2023?
- MARINUS PHARMACEUTICALS, INC. reported revenue of $31 million for fiscal 2023 (the year ended Dec 31, 2023), against $25.5 million the year before (+21.6%). Source: the 10-K filed with the SEC on Mar 5, 2024. SEC
- What was MARINUS PHARMACEUTICALS, INC.'s operating income in fiscal 2023?
- MARINUS PHARMACEUTICALS, INC. reported operating income of -$131.5 million for fiscal 2023 (the year ended Dec 31, 2023), against -$112.8 million the year before. Source: the 10-K filed with the SEC on Mar 5, 2024. SEC
- What was MARINUS PHARMACEUTICALS, INC.'s net income in fiscal 2023?
- MARINUS PHARMACEUTICALS, INC. reported net income of -$141.4 million for fiscal 2023 (the year ended Dec 31, 2023), against -$19.8 million the year before. Source: the 10-K filed with the SEC on Mar 5, 2024. SEC
- What was MARINUS PHARMACEUTICALS, INC.'s cash from operating activities in fiscal 2023?
- MARINUS PHARMACEUTICALS, INC. reported cash from operating activities of -$118 million for fiscal 2023 (the year ended Dec 31, 2023), against -$112.9 million the year before. Source: the 10-K filed with the SEC on Mar 5, 2024. SEC
- What are MARINUS PHARMACEUTICALS, INC.'s total assets?
- As of Dec 31, 2023, MARINUS PHARMACEUTICALS, INC. reported total assets of $170.9 million, against $259.5 million a year earlier (-34.1%). Source: the 10-K filed with the SEC on Mar 5, 2024. SEC
- What are MARINUS PHARMACEUTICALS, INC.'s total liabilities?
- As of Dec 31, 2023, MARINUS PHARMACEUTICALS, INC. reported total liabilities of $154.1 million, against $143.5 million a year earlier (+7.4%). Source: the 10-K filed with the SEC on Mar 5, 2024. SEC
- What are MARINUS PHARMACEUTICALS, INC.'s cash and cash equivalents?
- As of Dec 31, 2023, MARINUS PHARMACEUTICALS, INC. reported cash and cash equivalents of $120.6 million, against $240.6 million a year earlier (-49.9%). Source: the 10-K filed with the SEC on Mar 5, 2024. SEC
Read from the FinancialMD API on Nov 13, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.
The same numbers for an agent, with proof on every value:
curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=cik:1267813&period_type=annual&limit=5"Information only, not investment advice.